Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us


Global Inflammatory Bowel Disease (IBD) Treatment Market to Grow at 2.6% CAGR through 2025

Press release Description

Albany, New York, March 30, 2018: A new thorough study titled “Inflammatory Bowel Disease (IBD) Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” has recently been submitted to the database of Market Research Reports Search Engine (MRRSE). The global inflammatory bowel disease treatment market is projected to grow at 2.6% CAGR through 2025. In terms of revenue, the market is anticipated to reach nearly US$ 15 Bn in revenues.

The report offers detailed insights on the global inflammatory bowel disease treatment market, highlighting the key dynamics that are shaping this landscape. According to the report, increasing prevalence of Crohn’s disease and Ulcerative Colitis is likely to fuel the demand for inflammatory bowel disease treatment products and services. Product developments and rising incidents of IBD are also likely to fuel market growth during the assessment period. Some of the factors that can challenge the market players include easy availability of biosimilars copies.

The report segments the global inflammatory bowel disease treatment market into disease indication, distribution channel, drug class and region. The disease indication segment is further bifurcated into crohn’s disease and ulcerative colitis. The distribution channel segment is further sub-segmented into online pharmacy, retail pharmacy and hospital pharmacy. The drug class segment is categorized into corticosteroids, immunomodulators, aminosalicyclates and TNF inhibitors. Geographically, the market is divided into key regions globally which are North America, Latin America, Europe, Asia Pacific and Middle East & Africa.

On the basis of drug class, TNF inhibitors are likely to account for a dominant share of the global market. In terms of revenue share, aminosalicyclates accounted for the second largest revenue share of the market, however, during the assessment period, this segment is likely to lose share to immunomodulators. Patent expiry of some of the leading drugs is likely to be a key factor for the decline in immunomodulators.

By region, the report projects North America to be one of the leading markets for inflammatory bowel disease treatment. The market in North America is likely to remain concentrated in the US. High prevalence of IBD in the US is one of the key factors for the growth of the market in the region.

The report profiles some of the leading players operating in the market. Some of these players are Biogen Inc., Novartis AG, UCB Inc., AbbVie, Inc., Allergan plc., Takeda Pharmaceutical Company Limited., Allergan plc., Valeant Pharmaceuticals International, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Pfizer, Inc. and Shire plc.

Browse Full Global Inflammatory Bowel Disease (IBD) Treatment Market Report with TOC :

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords. 

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.


State Tower
90, State Street
Suite 700
Albany, NY – 12207
United States

Telephone: +1-518-730-0559